2003
DOI: 10.1002/hlca.200390171
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis of 6‐Amino Acid Substituted Derivatives of the Highly Potent Analgesic 14‐O‐Methyloxymorphone

Abstract: The novel morphinans 13 ± 18, which carry amino acid substituents at C(6), with potentially limited access to the central nervous system were prepared in two steps from 14-O-methyloxymorphone (5). Reductive amination with amino acid tert-butyl esters gave compounds 7 ± 12, which were hydrolyzed with tetrafluoroboric acid. Structure elucidation (including X-ray analysis), preliminary m-opioid receptor binding studies, and calculations of pharmacokinetic parameters were carried out.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

5
24
0

Year Published

2004
2004
2021
2021

Publication Types

Select...
8
1

Relationship

3
6

Authors

Journals

citations
Cited by 16 publications
(30 citation statements)
references
References 33 publications
5
24
0
Order By: Relevance
“…In a model of neuropathic pain, systemically (subcutaneously) applied loperamide reversed mechanical allodynia by activation of peripheral -receptors (Guan et al, 2008). Peripheral restriction was further pursued with arylacetamide morphinan-based [nalfurafine, [8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid (DiPOA)] and with peptidic compounds [Tyr-Arg-Phe-Lys-NH 2 (DALDA)] (for reviews, see Schü tz et al, 2003;DeHavenHudkins and Dolle, 2004;Chu et al, 2007). Some of these were subsequently abandoned, mostly because the chemical addition of hydrophilic residues led to reduced affinity at opioid receptors or because higher doses were able to penetrate the blood-brain barrier.…”
Section: Peripherally Acting Exogenous Opioid Agonistsmentioning
confidence: 99%
“…In a model of neuropathic pain, systemically (subcutaneously) applied loperamide reversed mechanical allodynia by activation of peripheral -receptors (Guan et al, 2008). Peripheral restriction was further pursued with arylacetamide morphinan-based [nalfurafine, [8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid (DiPOA)] and with peptidic compounds [Tyr-Arg-Phe-Lys-NH 2 (DALDA)] (for reviews, see Schü tz et al, 2003;DeHavenHudkins and Dolle, 2004;Chu et al, 2007). Some of these were subsequently abandoned, mostly because the chemical addition of hydrophilic residues led to reduced affinity at opioid receptors or because higher doses were able to penetrate the blood-brain barrier.…”
Section: Peripherally Acting Exogenous Opioid Agonistsmentioning
confidence: 99%
“…(29) These compounds displayed high affinities at the μ opioid receptor and showed potent agonism. (30) A number of pharmacological studies reported that amino acid substitution in position 6 of 14- O -methyloxymorphone affords derivatives that produce potent antinociceptive actions in rodent models of acute nociception, inflammatory, visceral, and neuropathic pain.…”
Section: Introductionmentioning
confidence: 99%
“… 11 We and others have reported on the incorporation of amino acid residues at position 6 of N -methylmorphinan-6-ones. 12 The 6-amino acid zwitterionic conjugates of 2 were established as MOR agonists inducing potent and long-lasting peripherally mediated antinociceptive effects after systemic administration. 4 , 5a , 13 The 6β-glycine substituted derivative of 2 was equipotent to fentanyl in the tail-flick assay in rats, acting via activation of peripherally located opioid receptors.…”
mentioning
confidence: 99%